Objective: To evaluate the long-term implantation effect on the Ahmed glaucoma valve treatment for neovascular glaucoma. Methods: 24 patients (24 eyes) with neovascular glaucoma were given aqueous drainage valve, and the in traocular pressure, visual acuity and complications were observed for 13-26 months [average (18.05 ±3.81) months], with the surgical success criteria of intraocular pressure <21 mm Hg, without serious complications, and intraocular pressure lowering IOP<21 mm Hg under medicine control. Results: After the end of follow-up, among the 24 cases of patients with neovascular glaucoma, there was 1 case with bacterial corneal ulcer perforation and had to remove the drainage tray, 1 case of intractable shallow anterior chamber and corneal decompensation, 7 cases required IOP lowering medication, 15 cases successed. The success rate of Ahmed aqueous drainage valve implantation for neovascular glaucoma was 66.67%, qualified success rate was 83.33%. The mean preoperative IOP was (40.24±13.80) mm Hg, the average IOP was (15.14±8.56) mm Hg at the end of the follow-up, which was significantly lower than that before surgery, the difference was statistically significant (P=0.00). The visual acuity before compared with after the operation, 10 eyes (41.67%) was leveled, 14 eyes (58.33%) was improved and no eye worsened. Among the early postoperative complications, there were 6 cases (25.00%) with the transient hyphema, 10 patients (41.67%) with the shallow anterior chambe, 4 cases (16.67%) with the conjunctival flap loose, and all cases were improved after treatment. Among the long-term complications, there was 1 case (4.17%) with the complicated cataract, 1 case (4.17%) with the corneal endothelial decompensation. Conclusion: Glaucoma drainage implantation surgery is an effective means to cure neovascular glaucoma, the surgery can significantly reduce intraocular pressure, provide long-term positive effect, save the residual visual function, and improve the patients 'life quality.%目的:评价前房型Ahmed房水引流阀植入治疗新生血管性青光眼(neovascular glaucoma,NVG)的远期疗效.方法:对24例(24只眼)NVG患者施行Ahmed房水引流阀植入术并观察术后眼压、视力及并发症情况,以随访结束时眼压<21 mm Hg(1 mm Hg=0.133 kPa)、无严重并发症为手术成功标准,降眼压药物控制下眼压<21 mm Hg为条件成功标准.随访13～26个月,平均(18.05±3.81)个月.结果:24例NVG患者中,1例合并细菌性角膜溃疡穿孔予取出引流盘,1例出现顽固性浅前房并角膜失代偿,7例需降眼压药物治疗,15例获得成功.Ahmed房水引流阀植入NVG成功率为66.67%,条件成功率为83.33%.术前平均眼压(40.24±13.80)mm Hg,随访结束时平均眼压(15.14±8.56)mm Hg,较之术前明显降低,差异有统计学意义(P=0.00).术后视力维持术前水平10例(41.67%),视力提高14例(58.33%).术后早期并发症有暂时性前房出血6例(25.00%)、浅前房10例(41.67%)、结膜瓣松脱4例(16.67%),经治疗后均好转;远期并发症有并发性白内障1例(4.17%)、角膜内皮失代偿1例(4.17%).结论:青光眼引流物植入术为治疗NVG的有效手段,能显著降低眼压,且远期疗效肯定,挽救患者残余视功能,提高患者生活质量.
展开▼
